Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) traded up 4.7% on Monday . The company traded as high as $22.35 and last traded at $22.74. 203,750 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 848,640 shares. The stock had previously closed at $21.73.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Citigroup initiated coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. William Blair initiated coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday. JMP Securities restated a "market outperform" rating and issued a $89.00 target price on shares of Structure Therapeutics in a research note on Monday. Finally, HC Wainwright lowered their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $76.17.
Check Out Our Latest Stock Analysis on Structure Therapeutics
Structure Therapeutics Stock Down 3.3%
The company has a market cap of $1.21 billion, a PE ratio of -24.23 and a beta of -1.87. The business has a 50-day simple moving average of $23.46 and a 200-day simple moving average of $24.04.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). On average, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.
Hedge Funds Weigh In On Structure Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC boosted its position in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Structure Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock valued at $1,240,000 after acquiring an additional 480 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its position in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. LPL Financial LLC lifted its position in shares of Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after acquiring an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after acquiring an additional 843 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.
Structure Therapeutics Company Profile
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Stories
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
